IL129286A0 - Reshaped human anti-HM 1.24 antibody - Google Patents
Reshaped human anti-HM 1.24 antibodyInfo
- Publication number
- IL129286A0 IL129286A0 IL12928697A IL12928697A IL129286A0 IL 129286 A0 IL129286 A0 IL 129286A0 IL 12928697 A IL12928697 A IL 12928697A IL 12928697 A IL12928697 A IL 12928697A IL 129286 A0 IL129286 A0 IL 129286A0
- Authority
- IL
- Israel
- Prior art keywords
- chain
- antibody
- human
- reshaped human
- region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26475696 | 1996-10-04 | ||
PCT/JP1997/003553 WO1998014580A1 (fr) | 1996-10-04 | 1997-10-03 | Anticorps anti-hm1.24 humain reconstitue |
Publications (1)
Publication Number | Publication Date |
---|---|
IL129286A0 true IL129286A0 (en) | 2000-02-17 |
Family
ID=17407753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12928697A IL129286A0 (en) | 1996-10-04 | 1997-10-03 | Reshaped human anti-HM 1.24 antibody |
Country Status (20)
Country | Link |
---|---|
US (2) | US6699974B2 (de) |
EP (1) | EP0960936B1 (de) |
KR (1) | KR100388256B1 (de) |
CN (2) | CN1765928A (de) |
AT (1) | ATE512224T1 (de) |
AU (1) | AU715156B2 (de) |
BR (1) | BR9712488A (de) |
CA (1) | CA2267072C (de) |
CZ (1) | CZ296790B6 (de) |
HK (1) | HK1024261A1 (de) |
IL (1) | IL129286A0 (de) |
NO (1) | NO325178B1 (de) |
PL (1) | PL187642B1 (de) |
RU (1) | RU2184147C2 (de) |
SK (1) | SK44399A3 (de) |
TR (1) | TR199900722T2 (de) |
TW (1) | TW530064B (de) |
UA (1) | UA76934C2 (de) |
WO (1) | WO1998014580A1 (de) |
ZA (1) | ZA978865B (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035698A1 (fr) * | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
WO1998037913A1 (fr) * | 1997-02-28 | 1998-09-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs d'activation de lymphocytes |
CN1326565C (zh) * | 1997-10-14 | 2007-07-18 | 中外制药株式会社 | 淋巴细胞肿瘤抗体的增强剂 |
WO1999043703A1 (fr) * | 1998-02-25 | 1999-09-02 | Chugai Seiyaku Kabushiki Kaisha | Technique de dosage immunochimique de l'anticorps anti-hm1.24 |
US6602663B1 (en) | 1998-09-18 | 2003-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method for detection or measuring plasmocytoma cells |
ES2241599T3 (es) * | 1999-05-10 | 2005-11-01 | Chugai Seiyaku Kabushiki Kaisha | Metodo de cultivo de celulas. |
DE60039893D1 (de) | 1999-08-23 | 2008-09-25 | Chugai Pharmaceutical Co Ltd | |
AU2001246846A1 (en) * | 2000-04-06 | 2001-10-23 | Chugai Seiyaku Kabushiki Kaisha | Immunoassay of anti-hm1.24 antibody |
ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
ATE457318T1 (de) * | 2000-12-28 | 2010-02-15 | Kyowa Hakko Kirin Co Ltd | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |
WO2002064159A1 (en) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedies for tumor in hematopoietic organs |
WO2002072615A1 (fr) | 2001-03-09 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Methode de purification de proteines |
CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
US7776612B2 (en) | 2001-04-13 | 2010-08-17 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying antigen expression |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
DE60228721D1 (en) * | 2001-06-22 | 2008-10-16 | Chugai Pharmaceutical Co Ltd | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper |
CA2450898A1 (en) * | 2001-07-09 | 2003-01-23 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
EP3192528A1 (de) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formularierung anti-il-6r antikörper-enthaltender lösungen die einen zucker als stabilisator beinhalten |
US20080219974A1 (en) * | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
AU2003239966B9 (en) * | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
JP4489591B2 (ja) | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
SI2261230T1 (sl) * | 2002-09-11 | 2017-08-31 | Chugai Seiyaku Kabushiki Kaisha | Postopek čiščenja proteinov |
US20060020119A1 (en) * | 2004-03-29 | 2006-01-26 | Stephen Grimes | Monoclonal antibodies to gastrin hormone |
CA2520010C (en) * | 2003-03-28 | 2012-07-10 | Aphton Corporation | Gastrin hormone immunoassays |
KR20060069825A (ko) * | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열 |
EP1666501A4 (de) * | 2003-08-11 | 2008-12-24 | Chugai Pharmaceutical Co Ltd | Zuckerkettenmodifizierter anti-hm1.24-antikörper |
US8603481B2 (en) * | 2003-10-10 | 2013-12-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for solid tumors |
TR201809892T4 (tr) * | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
EP2168986A3 (de) * | 2004-02-19 | 2010-07-28 | Genentech, Inc. | Antikörper mit korrigiertem CDR |
JP2008513536A (ja) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
KR101460932B1 (ko) * | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
AU2012216702B2 (en) * | 2005-08-26 | 2014-12-04 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (de) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Bindende polypeptide mit eingeschränkten diversitätssequenzen |
EP1977763A4 (de) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | Antikörper-enthaltende stabilisierende zubereitung |
EP2064240A2 (de) * | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimierte auf hm1.24 abzielende antikörper |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
PL3023438T3 (pl) | 2009-09-03 | 2020-07-27 | Merck Sharp & Dohme Corp. | Przeciwciała anty-gitr |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
EP2750784A1 (de) | 2011-09-01 | 2014-07-09 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur herstellung einer zusammensetzung mit hochkonzentrierten antikörpern durch ultrafiltration |
RU2714967C2 (ru) | 2013-12-27 | 2020-02-21 | Чугаи Сейяку Кабусики Кайся | Способ очистки антител с низкой изоэлектрической точкой |
JP6858559B2 (ja) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | 蛋白質溶液の粘度測定方法 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
CN109748964B (zh) * | 2017-11-01 | 2020-11-17 | 深圳宾德生物技术有限公司 | CD317单链抗体317scFv、其编码序列及制备方法和应用 |
CN113226367A (zh) | 2018-04-06 | 2021-08-06 | Atyr 医药公司 | 包括抗nrp2抗体的组合物和方法 |
KR20210010996A (ko) | 2018-05-21 | 2021-01-29 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
EP3805112A4 (de) | 2018-05-28 | 2022-03-09 | Chugai Seiyaku Kabushiki Kaisha | Fülldüse |
JP2022551603A (ja) | 2019-10-03 | 2022-12-12 | エータイアー ファーマ, インコーポレイテッド | 抗nrp2抗体を含む組成物および方法 |
WO2023058705A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | 抗hla-dq2.5抗体の製剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO873164L (no) * | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
WO1998035698A1 (fr) * | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
US20020034507A1 (en) * | 1997-02-28 | 2002-03-21 | Yasuo Koishihara | Inhibitor of lymphocyte activation |
EP1020522B1 (de) * | 1997-10-03 | 2007-09-19 | Chugai Seiyaku Kabushiki Kaisha | Natürlicher menschlicher antikörper |
CN1326565C (zh) * | 1997-10-14 | 2007-07-18 | 中外制药株式会社 | 淋巴细胞肿瘤抗体的增强剂 |
EP1517921B1 (de) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual-specifische liganden mit erhöhter halbwertszeit |
-
1997
- 1997-03-10 UA UA99042469A patent/UA76934C2/uk unknown
- 1997-10-03 RU RU99109034/13A patent/RU2184147C2/ru not_active IP Right Cessation
- 1997-10-03 CZ CZ0117399A patent/CZ296790B6/cs not_active IP Right Cessation
- 1997-10-03 TR TR1999/00722T patent/TR199900722T2/xx unknown
- 1997-10-03 TW TW086114474A patent/TW530064B/zh not_active IP Right Cessation
- 1997-10-03 SK SK443-99A patent/SK44399A3/sk unknown
- 1997-10-03 IL IL12928697A patent/IL129286A0/xx not_active IP Right Cessation
- 1997-10-03 US US09/269,921 patent/US6699974B2/en not_active Expired - Lifetime
- 1997-10-03 CA CA002267072A patent/CA2267072C/en not_active Expired - Fee Related
- 1997-10-03 BR BR9712488-5A patent/BR9712488A/pt not_active Application Discontinuation
- 1997-10-03 CN CNA2005100687876A patent/CN1765928A/zh active Pending
- 1997-10-03 WO PCT/JP1997/003553 patent/WO1998014580A1/ja active IP Right Grant
- 1997-10-03 EP EP97942246A patent/EP0960936B1/de not_active Expired - Lifetime
- 1997-10-03 AU AU43992/97A patent/AU715156B2/en not_active Ceased
- 1997-10-03 PL PL97332742A patent/PL187642B1/pl not_active IP Right Cessation
- 1997-10-03 ZA ZA9708865A patent/ZA978865B/xx unknown
- 1997-10-03 AT AT97942246T patent/ATE512224T1/de not_active IP Right Cessation
- 1997-10-03 CN CNB971992150A patent/CN1271205C/zh not_active Expired - Fee Related
- 1997-10-03 KR KR10-1999-7002902A patent/KR100388256B1/ko not_active IP Right Cessation
-
1999
- 1999-03-31 NO NO19991591A patent/NO325178B1/no unknown
-
2000
- 2000-03-23 HK HK00101791A patent/HK1024261A1/xx not_active IP Right Cessation
-
2002
- 2002-08-13 US US10/218,253 patent/US7892543B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CZ296790B6 (cs) | 2006-06-14 |
US20030045691A1 (en) | 2003-03-06 |
CN1235639A (zh) | 1999-11-17 |
KR100388256B1 (ko) | 2003-06-19 |
NO991591L (no) | 1999-06-01 |
TW530064B (en) | 2003-05-01 |
US6699974B2 (en) | 2004-03-02 |
CA2267072A1 (en) | 1998-04-09 |
PL187642B1 (pl) | 2004-08-31 |
CN1271205C (zh) | 2006-08-23 |
EP0960936A4 (de) | 2005-01-19 |
EP0960936A1 (de) | 1999-12-01 |
KR20000048884A (ko) | 2000-07-25 |
SK44399A3 (en) | 2000-05-16 |
PL332742A1 (en) | 1999-10-11 |
RU2184147C2 (ru) | 2002-06-27 |
ZA978865B (en) | 1998-04-20 |
CN1765928A (zh) | 2006-05-03 |
NO325178B1 (no) | 2008-02-11 |
HK1024261A1 (en) | 2000-10-05 |
ATE512224T1 (de) | 2011-06-15 |
NO991591D0 (no) | 1999-03-31 |
US20030129185A1 (en) | 2003-07-10 |
UA76934C2 (en) | 2006-10-16 |
BR9712488A (pt) | 1999-10-19 |
WO1998014580A1 (fr) | 1998-04-09 |
CA2267072C (en) | 2004-11-30 |
AU4399297A (en) | 1998-04-24 |
US7892543B2 (en) | 2011-02-22 |
EP0960936B1 (de) | 2011-06-08 |
TR199900722T2 (xx) | 1999-12-21 |
CZ117399A3 (cs) | 1999-09-15 |
AU715156B2 (en) | 2000-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL129286A0 (en) | Reshaped human anti-HM 1.24 antibody | |
AU2936395A (en) | Reconstituted human antibody against human interleukin-8 | |
IL138801A0 (en) | Humanized antibody against human tissue factor and process for the preparation thereof | |
EP1020522A4 (de) | Natürlicher menschlicher antikörper | |
IL148079A0 (en) | Human ctla-4 antibodies and compositions containing the same | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
FI861150A (fi) | Monoklonala antikroppar mot metallkelat. | |
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
NL300433I2 (en) | Methods and compositions for the treatment of glomerulonephritis. | |
BG101966A (en) | Application of 1l-agonist for the treatment of lack of urine retention | |
CY2583B2 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
WO1991010735A3 (fr) | Recepteur humain de la tsh. sequence codant pour ce recepteur | |
AU4441393A (en) | Granulocyte-binding antibody fragments, their preparation and use | |
ITBO940254A0 (it) | Metodo per il miglioramento di alcune funzionalita' del corpo umano. | |
RU93035807A (ru) | Способ лечения юношеского эпифизиолиса |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |